ArticleThe Journal of infectious diseases2019
Risk Factors and Attack Rates of Seasonal Influenza Infection: Results of the Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance (SHIVERS) Seroepidemiologic Cohort Study.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Anti-neuraminidase and anti-HA stalk antibodies reduce the susceptibility to and infectivity of influenza A/H3N2 virus.Nature communications · 2025Article
- Multiplex serology reveals age-specific immunodynamics of respiratory pathogens in the wake of the COVID-19 pandemic.Nature communications · 2025Article
- A Framework for Evaluating the Use of Surveillance Systems for Short-Term Influenza Forecasting.Influenza and other respiratory viruses · 2025Article
- Multiplex serology reveals age-specific immunodynamics of endemic respiratory pathogens in the wake of the COVID-19 pandemic.medRxiv : the preprint server for health sciences · 2025Article
- How immunity shapes the long-term dynamics of influenza H3N2.PLoS computational biology · 2025Article
- A Potential Platform for Future Vaccine Trials Identifies a High Incidence of Symptomatic and Asymptomatic Influenza Infection Among Children Aged 6 to 23 Months in South Africa.The Journal of infectious diseases · 2025Article
- Investigation of Influenza Cases and Risk Factors Associated with Fatality in Türkiye.Sisli Etfal Hastanesi tip bulteni · 2025Article
- A comparative analysis of influenza and COVID-19: Environmental-ecological impacts, socioeconomic implications, and future challenges.Biosafety and health · 2024Review
- Reconstructed influenza A/H3N2 infection histories reveal variation in incidence and antibody dynamics over the life course.PLoS biology · 2024Article
- Evaluating equity-promoting interventions to prevent race-based inequities in influenza outcomes.medRxiv : the preprint server for health sciences · 2024Article
- Reconstructed influenza A/H3N2 infection histories reveal variation in incidence and antibody dynamics over the life course.medRxiv : the preprint server for health sciences · 2024Article
- An Intense Out-of-Season Rebound of Influenza Activity After the Relaxation of Coronavirus Disease 2019 Restrictions in Beijing, China.Open forum infectious diseases · 2024Article
- Baseline innate and T cell populations are correlates of protection against symptomatic influenza virus infection independent of serology.Nature immunology · 2023Article
- Article
- Preschool-Aged Household Contacts as a Risk Factor for Viral Respiratory Infections in Healthcare Personnel.Open forum infectious diseases · 2023Article
- Evaluation of determinants of the serological response to the quadrivalent split-inactivated influenza vaccine.Molecular systems biology · 2022Article
- The Antibody Response Against Neuraminidase in Human Influenza A (H3N2) Virus Infections During 2018/2019 Flu Season: Focusing on the Epitopes of 329-Frontiers in microbiology · 2022Article
- From Outbreak to Near Disappearance: How Did Non-pharmaceutical Interventions Against COVID-19 Affect the Transmission of Influenza Virus?Frontiers in public health · 2022Article
- Comprehensive Immunologic Evaluation of Bronchoalveolar Lavage Samples from Human Patients with Moderate and Severe Seasonal Influenza and Severe COVID-19.Journal of immunology (Baltimore, Md. : 1950) · 2021Observational
- Antibody Responsiveness to Influenza: What Drives It?Viruses · 2021Review
Corrections and comments
- Commented on by
Authors and funding
39 authors.
Funding
Abstract
Background: Understanding the attack rate of influenza infection and the proportion who become ill by risk group is key to implementing prevention measures. While population-based studies of antihemagglutinin antibody responses have been described previously, studies examining both antihemagglutinin and antineuraminidase antibodies are lacking. Methods: In 2015, we conducted a seroepidemiologic cohort study of individuals randomly selected from a population in New Zealand. We tested paired sera for hemagglutination inhibition (HAI) or neuraminidase inhibition (NAI) titers for seroconversion. We followed participants weekly and performed influenza polymerase chain reaction (PCR) for those reporting influenza-like illness (ILI). Results: Influenza infection (either HAI or NAI seroconversion) was found in 321 (35% [95% confidence interval, 32%-38%]) of 911 unvaccinated participants, of whom 100 (31%) seroconverted to NAI alone. Young children and Pacific peoples experienced the highest influenza infection attack rates, but overall only a quarter of all infected reported influenza PCR-confirmed ILI, and one-quarter of these sought medical attention. Seroconversion to NAI alone was higher among children aged <5 years vs those aged ≥5 years (14% vs 4%; P < .001) and among those with influenza B vs A(H3N2) virus infections (7% vs 0.3%; P < .001). Conclusions: Measurement of antineuraminidase antibodies in addition to antihemagglutinin antibodies may be important in capturing the true influenza infection rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.